Vioxx, the implosion of Merck, and aftershocks at the FDA

Lancet. 2004 Dec 4-10;364(9450):1995-6. doi: 10.1016/S0140-6736(04)17523-5.
No abstract available

Publication types

  • Comment

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects*
  • Cardiovascular Diseases / chemically induced*
  • Cyclooxygenase Inhibitors / adverse effects*
  • Drug Approval
  • Drug Industry*
  • Drug Information Services
  • Humans
  • Interinstitutional Relations*
  • Lactones / adverse effects*
  • Safety
  • Sulfones / adverse effects*
  • United States
  • United States Food and Drug Administration*

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Cyclooxygenase Inhibitors
  • Lactones
  • Sulfones
  • rofecoxib